Greenbrook TMS Inc. (TSX: GTMS, NASDAQ: GBNH)
(“Greenbrook” or the “Company”) today announced that
it has completed a non-brokered private placement (the “Private
Placement”) of common shares of the Company (the “Common
Shares”). Pursuant to the Private Placement, an aggregate of
2,353,347 Common Shares were issued at a price of US$10.00 per
share, for aggregate gross proceeds to the Company of approximately
US$23.5 million. The financing was led by new investor Masters
Special Situations, LLC and affiliates thereof (“MSS”). In
connection with the Private Placement, MSS will receive the right
to appoint a nominee to the board of directors of the Company.
Additional new investors, including BioStar Capital, also
participated in the financing, along with existing investors,
Greybrook Health Inc. (“Greybrook Health”) and 1315 Capital
II, L.P. (“1315 Capital”).
The Company intends to use the proceeds from the Private
Placement for the development of new mental health service centers
that specialize in Transcranial Magnetic Stimulation (“TMS”)
treatment as well as working capital and general corporate
purposes.
The offer and sale of the Common Shares in the Private Placement
was made in the United States solely to accredited investors
pursuant to the exemption from registration in Rule 506(c) of
Regulation D promulgated by the United States Securities and
Exchange Commission (the “SEC”) under the United States
Securities Act of 1933, as amended (the “Securities Act”)
and in Canada pursuant to and in compliance with exemptions from
the prospectus requirements of applicable Canadian securities
laws.
In connection with the Private Placement, MSS, Greybrook Health
and 1315 Capital will each receive the right to appoint a nominee
to the board of directors of the Company, and all investors will
receive customary registration rights.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any securities in any jurisdiction
in which such offer, solicitation or sale would be unlawful.
MI 61-101 Disclosure
Greybrook Health and 1315 Capital are each insiders of the
Company. Accordingly, the Private Placement is considered a
“related party transaction” for purposes of Multilateral Instrument
61-101 – Protection of Minority Security Holders in Special
Transactions (“MI 61-101”). Pursuant to MI 61-101, the
Company will file a material change report providing disclosure in
relation to each “related party transaction” on SEDAR under the
Company’s issuer profile at www.sedar.com. The Company did not file
the material change report more than 21 days before the expected
closing date of the Private Placement as the details of the Private
Placement and the participation therein by the “related parties” of
the Company were not settled until shortly prior to the closing of
the Private Placement, and the Company wished to close the Private
Placement on an expedited basis for business reasons.
The Company is relying on exemptions from the formal valuation
and minority shareholder approval requirements available under MI
61-101. The Company is exempt from the formal valuation requirement
in section 5.4 of MI 61-101 in reliance on section 5.5(a) of MI
61-101 as the fair market value of the transaction, insofar as it
involves interested parties, is not more than 25% of the Company’s
market capitalization. Additionally, the Company is exempt from the
minority shareholder approval requirement in section 5.6 of MI
61-101 in reliance on section 5.7(1)(a) as the fair market value of
the transaction, insofar as it involves interested parties, is not
more than 25% of the Company’s market capitalization.
About Greenbrook TMS Inc.
Operating through 128 Company-operated treatment centers,
Greenbrook is a leading provider of TMS therapy, an FDA-cleared,
non-invasive therapy for the treatment of Major Depressive Disorder
and other mental health disorders, in the United States. TMS
therapy provides local electromagnetic stimulation to specific
brain regions known to be directly associated with mood regulation.
Greenbrook has provided more than 620,000 TMS treatments to over
17,000 patients struggling with depression.
About Masters Special Situations, LLC
MSS is an affiliate of Masters Capital Management, LLC, an SEC
registered investment adviser based in Atlanta, Georgia. MSS
invests growth capital in innovative, small cap public companies in
North America.
Cautionary Note Regarding Forward-Looking Information
Certain information in this press release, including with
respect to the Private Placement, including the anticipated use of
proceeds thereof, constitutes forward-looking information within
the meaning of applicable securities laws in Canada and the United
States, including the United States Private Securities Litigation
Reform Act of 1995. In some cases, but not necessarily in all
cases, forward-looking information can be identified by the use of
forward-looking terminology such as “plans”, “targets”, “expects”
or “does not expect”, “is expected”, “an opportunity exists”, “is
positioned”, “estimates”, “intends”, “assumes”, “anticipates” or
“does not anticipate” or “believes”, or variations of such words
and phrases or state that certain actions, events or results “may”,
“could”, “would”, “might”, “will” or “will be taken”, “occur” or
“be achieved”. In addition, any statements that refer to
expectations, projections or other characterizations of future
events or circumstances contain forward-looking information.
Statements containing forward-looking information are not
historical facts but instead represent management’s expectations,
estimates and projections regarding future events.
Forward-looking information is necessarily based on a number of
opinions, assumptions and estimates that, while considered
reasonable by the Company as of the date of this press release, are
subject to known and unknown risks, uncertainties, assumptions and
other factors that may cause the actual results, level of activity,
performance or achievements to be materially different from those
expressed or implied by such forward-looking information, including
but not limited to the factors described in greater detail in the
“Risk Factors” section of the Company’s current annual information
form and in the Company’s other materials filed with the Canadian
securities regulatory authorities and the SEC from time to time,
available at www.sedar.com and www.sec.gov, respectively. These
factors are not intended to represent a complete list of the
factors that could affect the Company; however, these factors
should be considered carefully. There can be no assurance that such
estimates and assumptions will prove to be correct. The
forward-looking statements contained in this press release are made
as of the date of this press release, and the Company expressly
disclaims any obligation to update or alter statements containing
any forward-looking information, or the factors or assumptions
underlying them, whether as a result of new information, future
events or otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210614005734/en/
Glen Akselrod Investor Relations Greenbrook TMS Inc. Email:
investorrelations@greenbrooktms.com Phone: 1-855-797-4867
Greenbrook TMS (TSX:GTMS)
Historical Stock Chart
Von Dez 2024 bis Jan 2025
Greenbrook TMS (TSX:GTMS)
Historical Stock Chart
Von Jan 2024 bis Jan 2025